Thrombin Inhibitor
Ximelagatran: direct thrombin inhibitor
... direct thrombin inhibitor ximelagatran in patients with recent myocardial damage) study (Wallentin et al 2003) was a phase II study assessing the efficacy and safety of ximelagatran in preventing recurrent ...
10
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders
... Abstract: Venous thromboembolism, presenting as deep vein thrombosis or pulmonary embolism, is a major challenge for health care systems. It is the third most common vascular disease after coronary heart disease and ...
13
XIMELAGATRAN: A NEW DIRECT THROMBIN INHIBITOR
... pharmacodynamics. Thrombin is a key enzyme in the coagulation cascade and as such is an attractive target for novel anticoagulant ...of thrombin. Ximelagatran-the first oral direct thrombin ...
7
Wound problems following hip arthroplasty before and after the introduction of a direct thrombin inhibitor for thromboprophylaxis
... NICE guidelines have stated that patients undergoing elective hip surgery are at increased risk for venous thromboembolic events (VTE) following surgery and have recommended thromboprophylaxis for 28-35 days 1, 2 . ...
23
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
... Direct thrombin inhibitor dabigatran and factor Xa inhibitors like rivaroxaban and apixaban have already been approved by the US Food and Drug Administration (FDA) for stroke prevention in patients with ...
11
New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness
... Abstract: Atrial fibrillation (AF) continues to be a leading cause of cerebrovascular morbidity and mortality resulting from cardioembolic stroke. Oral anticoagulation therapy has been shown to decrease the incidence of ...
10
Unchecked thrombin is bad news for troubled arteries
... Might thrombin also contribute to longer-term, structural changes in the arterial wall that promote narrowing and clotting? A study in this issue of the JCI argues that it ...glycosaminoglycan-dependent ...
5
Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment
... inhibiting thrombin may enhance the anti-tumor efficacy of a chemotherapeutic agent when treating ovarian ...direct thrombin inhibitor, significantly inhibit ovarian cancer progression in the murine ...
15
Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism
... Xa inhibitor, was non-inferior to standard therapy with enoxaparin plus a vitamin K antagonist for the prevention of recurrent, symptomatic venous thromboembolism (VTE) in patients with acute PE and led to a 50% ...
9
Education and practice gaps on atrial fibrillation and anticoagulation: a survey of cardiovascular nurses
... the thrombin inhibitor dabigatran, and factor Xa inhibitors rivaroxaban and apixaban have held the promise of simplified dosing without the need for frequent blood testing, concerns persist of bleeding risk ...
10
Transitions of care in anticoagulated patients
... direct thrombin inhibitor, dabigatran etexilate, and the factor Xa inhibitors, rivaroxaban and apixaban, have been approved in the US for reducing the risk of stroke and systemic embolism in patients with ...
14
Developments in the management and treatment of pulmonary embolism
... Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE) study found that extended dabigatran (150 mg twice daily) for patients who had received anticoagulant ...
14
Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery
... direct thrombin inhibitor, approved in many regions or countries including Europe, Canada, and Australia for this indication; it has recently been in- cluded in guidelines for the prevention of VTE in pa- ...
7
Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus
... Fibrinogen (Haemochrom Diagnostica) or increasing concentrations (0.025 to 33.0 μg/mL) of thrombin (Hoffmann-La Roche) were incubated with purified human FXII (Enzyme Research Laboratories, 2.5 μg/mL) for 15 ...
10
New options with dabigatran etexilate in anticoagulant therapy
... Abstract: Thrombosis, the localized clotting of blood, occurs in both the arterial and venous circulation, and has a major impact on health outcomes. The primary etiology of myocardial infarctions, and approximately 80% ...
11
Regulation of expression of CPB2, the gene encoding human thrombin activatable fibrinolysis inhibitor (TAFI): the role for post-transcriptional regulation
... clot. Thrombin-activatable fibrinolysis inhibitor (TAFI, Human Genome Organization gene name carboxypeptidase B2, symbol CPB2), is a plasma protein that has been demonstrated to play key roles in ...
200
Association between polymorphisms in the flanking region of the TAFI gene and atherosclerotic cerebral infarction in a Chinese population
... that thrombin activatable fibrinolysis inhibitor (TAFI) may play an important role in the occurrence of acute cerebral infarction, and the levels of TAFI are affected by several single nucleotide ...
7
Original Article Thrombin-activatable fibrinolysis inhibitor (TAFI) is a potential biomarker for cerebral hemorrhage patients
... Abstract: Cerebral hemorrhage is the most common human cerebrovascular disease and frequently leads to pa- ralysis, a vegetative state, and even death. Previous studies have indicated that thrombin-activatable ...
7
Thrombosis in inflammatory bowel diseases: what’s the link?
... activator inhibitor 1 (PAI-1) that inhibits tPA activity in plasma [67], alpha2-antiplasmin which inhibits plasmin activity in plasma [68] and thrombin-activatable fibrinolysis inhibitor (TAFI) which ...
9
Effect of a 3-Week Low-Calorie Diet and Balneological Treatment on Selected Coagulation Parameters in Morbidly Obese Patients
... have a strong affinity for binding TFPI. Lipopro- tein-associated TFPI presents fewer anticoagulant properties than free TFPI [12, 17]. On the other hand, an increase in the expression of pro-inflam- matory ...
7